补中益气汤联合英夫利西单抗治疗活动性克罗恩病临床研究  

Clinical Study on Buzhong Yiqi Decoction Combined with Infliximab for Active Crohn Disease

作　　者：郑伟伟[1] ZHENG Weiwei

机构地区：[1]温州市中医院消化内科,浙江温州325000

出　　处：《新中医》2023年第2期23-27,共5页New Chinese Medicine

摘　　要：目的:观察补中益气汤联合英夫利西单抗治疗活动性克罗恩病的临床疗效,以及对患者免疫功能的影响。方法:按随机数字表法将86例活动性克罗恩病患者分为对照组和观察组,每组43例。对照组予以英夫利西单抗治疗,观察组在对照组基础上予以补中益气汤治疗。对比2组临床疗效、黏膜愈合率、复发率及不良反应发生率,观察2组治疗前后克罗恩病活动指数(CDAI)、克罗恩病内镜下严重指数(CDEIS)、免疫功能指标的变化。结果:观察组总有效率95.35%,高于对照组79.07%(P<0.05)。观察组黏膜愈合率88.37%,高于对照组69.77%(P<0.05)。观察组复发率5.56%,低于对照组35.71%(P<0.05)。治疗后,2组CDAI、CDEIS评分均较治疗前降低(P<0.05),观察组CDAI、CDEIS评分均低于对照组(P<0.05)。治疗后,2组血清CD3^(+)、CD4^(+)水平均较治疗前降低(P<0.05),血清CD4^(+)/CD25^(+)调节性T细胞(Treg)水平均较治疗前升高(P<0.05);观察组血清CD3^(+)、CD4^(+)水平均低于对照组(P<0.05),血清CD4^(+)/CD25^(+)Treg水平高于对照组(P<0.05)。观察组不良反应发生率9.30%,与对照组4.65%比较,差异无统计学意义(P>0.05)。结论:补中益气汤联合英夫利西单抗治疗活动性克罗恩病,可增强疗效、减少复发,并能改善患者的免疫功能,安全性高。Objective:To observe the clinical effect of Buzhong Yiqi Decoction combined with Infliximab for active Crohn disease and its effect on the immune function of patients.Methods:A total of 86 cases of patients with active Crohn disease were divided into the control group and the observation group according to the random number table method,with 43 cases in each group.The control group was treated with Infliximab,and the observation group was additionally treated with Buzhong Yiqi Decoction based on the treatment of the control group.Clinical effects,mucosa healing rates,recurrence rates and the incidence of adverse reactions were compared between the two groups.Changes in Crohn Disease Activity Index(CDAI),Crohn Disease Endoscopic Index of Severity(CDEIS)and indexes of immune function in the two groups before and after treatment were observed.Results:The total effective rate was 95.35% in the observation group,higher than that of 79.07% in the control group(P<0.05).The mucosa healing rate was 88.37% in the observation group,higher than that of 69.77% in the control group(P<0.05).The recurrence rate was 5.56% in the observation group,lower than that of 35.71% in the control group(P<0.05).After treatment,the scores of CDAI and CDEIS in the two groups were decreased when compared with those before treatment(P<0.05),and the two scores in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in serum in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of CD4^(+)/CD25^(+)regulatory T cell(Treg)in serum were increased when compared with those before treatment(P<0.05);the levels of CD3^(+)and CD4^(+)in serum in the observation group were lower than those in the control group(P<0.05),and the levels of CD4^(+)/CD25^(+)Treg in serum were higher than that in the control group(P<0.05).The incidence of adverse reactions were 9.30% in the observation group and 4.65% in the control group,there being no significance in th

关 键 词：活动性克罗恩病 补中益气汤 英夫利西单抗 克罗恩病活动指数 克罗恩病内镜下严重指数 复发 免疫功能 

分 类 号：R57[医药卫生—消化系统]